全文获取类型
收费全文 | 8639篇 |
免费 | 507篇 |
国内免费 | 73篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 751篇 |
妇产科学 | 333篇 |
基础医学 | 721篇 |
口腔科学 | 137篇 |
临床医学 | 905篇 |
内科学 | 2221篇 |
皮肤病学 | 156篇 |
神经病学 | 741篇 |
特种医学 | 270篇 |
外国民族医学 | 5篇 |
外科学 | 765篇 |
综合类 | 418篇 |
一般理论 | 5篇 |
预防医学 | 684篇 |
眼科学 | 121篇 |
药学 | 496篇 |
中国医学 | 71篇 |
肿瘤学 | 385篇 |
出版年
2023年 | 69篇 |
2022年 | 93篇 |
2021年 | 139篇 |
2020年 | 97篇 |
2019年 | 91篇 |
2018年 | 175篇 |
2017年 | 158篇 |
2016年 | 151篇 |
2015年 | 145篇 |
2014年 | 131篇 |
2013年 | 355篇 |
2012年 | 625篇 |
2011年 | 664篇 |
2010年 | 250篇 |
2009年 | 219篇 |
2008年 | 531篇 |
2007年 | 614篇 |
2006年 | 495篇 |
2005年 | 551篇 |
2004年 | 642篇 |
2003年 | 607篇 |
2002年 | 496篇 |
2001年 | 415篇 |
2000年 | 178篇 |
1999年 | 178篇 |
1998年 | 186篇 |
1997年 | 90篇 |
1996年 | 70篇 |
1995年 | 43篇 |
1994年 | 50篇 |
1993年 | 52篇 |
1992年 | 68篇 |
1991年 | 66篇 |
1990年 | 55篇 |
1989年 | 35篇 |
1988年 | 39篇 |
1987年 | 44篇 |
1986年 | 37篇 |
1985年 | 34篇 |
1984年 | 24篇 |
1983年 | 20篇 |
1982年 | 15篇 |
1981年 | 15篇 |
1979年 | 15篇 |
1978年 | 15篇 |
1977年 | 13篇 |
1974年 | 12篇 |
1973年 | 17篇 |
1972年 | 12篇 |
1969年 | 12篇 |
排序方式: 共有9219条查询结果,搜索用时 0 毫秒
1.
2.
3.
4.
5.
6.
7.
G. Lallement Didier Clarençon Catherine Masqueliez Dominique Baubichon Monique Galonnier Marie-France Burckhart Michel Peoc’h Jean Claude Mestries 《Archives of toxicology》1997,72(2):84-92
Organophosphorus nerve agents are still in use today in warfare and as terrorism compounds. Classical emergency treatment
of organophosphate poisoning includes the combined administration of a cholinesterase reactivator (an oxime), a muscarinic
cholinergic receptor antagonist (atropine) and a benzodiazepine anticonvulsant (diazepam). However, recent experiments with
primates have demonstrated that such treatment, even when administered immediately after organophosphate exposure, does not
rapidly restore normal electroencephalographic (EEG) activity and fails to totally prevent neuronal brain damage. The objective
of this study was to evaluate, in a realistic setting, the therapeutic benefit of administration of GK-11 (gacyclidine), an
antiglutamatergic compound, as a complement to the available emergency therapy against organophosphate poisoning. GK-11 was
injected at a dose of 0.1 mg/kg (i.v) after a 45-min latency period to heavily intoxicated (8 LD50) primates. Just after intoxication, man-equivalent doses of one autoinjector containing atropine/pralidoxime/diazepam were
administered. The effects of GK-11 were examined on survival, EEG activity, signs of toxicity, recovery after challenge and
central nervous system histology. The present data demonstrate that treatment with GK-11 prevents the mortality observed after
early administration of classical emergency medication alone. EEG recordings and clinical observations also revealed that
GK-11 prevented soman-induced seizures and motor convulsions. EEG analysis within the classical frequency bands (beta, theta,
alpha, delta) demonstrated that central activity was totally restored to normal after GK-11 treatment, but remained profoundly
altered in animals receiving atropine/pralidoxime/diazepam alone. GK-11 also markedly accelerated clinical recovery of soman-challenged
primates. Lastly, this drug totally prevented the neuropathology observed 3 weeks after soman exposure in animals treated
with classical emergency treatment alone. GK-11 represents a promising adjuvant therapy to the currently available emergency
polymedication to ensure optimal management of organophosphate poisoning in man. This drug is presently being evaluated in
a human clinical trial for a different neuroprotective indication.
Received: 16 June 1997 / Accepted: 23 September 1997 相似文献
8.
9.
10.
F. Estelle R. Simons on Behalf of the Early Prevention of Asthma in Atopic Children Study Group 《Pediatric allergy and immunology》2007,18(6):535-542
There are more than 40 H(1)-antihistamines available worldwide. Most of these medications have never been optimally studied in prospective, randomized, double-masked, placebo-controlled trials in children. The aim was to perform a long-term study of levocetirizine safety in young atopic children. In the randomized, double-masked Early Prevention of Asthma in Atopic Children Study, 510 atopic children who were age 12-24 months at entry received either levocetirizine 0.125 mg/kg or placebo twice daily for 18 months. Safety was assessed by: reporting of adverse events, numbers of children discontinuing the study because of adverse events, height and body mass measurements, assessment of developmental milestones, and hematology and biochemistry tests. The population evaluated for safety consisted of 255 children given levocetirizine and 255 children given placebo. The treatment groups were similar demographically, and with regard to number of children with: one or more adverse events (levocetirizine, 96.9%; placebo, 95.7%); serious adverse events (levocetirizine, 12.2%; placebo, 14.5%); medication-attributed adverse events (levocetirizine, 5.1%; placebo, 6.3%); and adverse events that led to permanent discontinuation of study medication (levocetirizine, 2.0%; placebo, 1.2%). The most frequent adverse events related to: upper respiratory tract infections, transient gastroenteritis symptoms, or exacerbations of allergic diseases. There were no significant differences between the treatment groups in height, mass, attainment of developmental milestones, and hematology and biochemistry tests. The long-term safety of levocetirizine has been confirmed in young atopic children. 相似文献